LP
NYMX

LMR Partners’s Nymox Pharmaceutical Corp NYMX Stock Holding History

LMR Partners’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-34,819
Closed -$64K – 592
2019
Q3 		$64K Hold
34,819
– – ﹤0.01% 369
2019
Q2 		$50K Buy
+34,819
New +$60.9K ﹤0.01% 379

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return

LMR Partners's NYMX Position: Q4 2019 in Review

LMR Partners sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2019, closing a stake of 34,819 shares — an estimated $64K sold.

LMR Partners first reported a position in NYMX in Q2 2019 and held it in 2 quarters. The position peaked at $64K in Q3 2019. 45 funds tracked by Wall St. Rank hold NYMX as of Q4 2019.

  • LMR Partners reported no remaining Nymox Pharmaceutical Corp position as of Q4 2019 after selling out during the quarter.
  • LMR Partners sold 34,819 Nymox Pharmaceutical Corp shares in Q4 2019, an estimated $64K.
  • LMR Partners first reported a position in Nymox Pharmaceutical Corp in Q2 2019 and held it in 2 quarters.
  • LMR Partners's Nymox Pharmaceutical Corp position peaked at $64K in Q3 2019.
  • 45 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2019.

Based on LMR Partners's 13F filing for Q4 2019, filed 14 Feb 2020.